One-day versus two-day chemotherapy for unresectable liver cancer
Part of Cancer, Digestive system clinical trials.
This study compares two schedules of chemotherapy to treat liver cancer that cannot be removed with surgery. It aims to see whether the shorter schedule works about as well, with similar safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- Your general health score is high (KPS 70 or higher)
- You have liver cancer (HCC) that is not removable by surgery, and it has stage A, B, or C
- At least one tumor spot can be measured on scans
- Your liver function and blood tests fall within required ranges (including bilirubin, albumin, blood counts)
- You can understand the study and sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
This trial studies HAIC, a type of targeted treatment delivered into the liver, for advanced hepatocellular carcinoma (liver cancer) that has already been treated with immune and anti-blood-vessel therapies. It aims to see whether HAIC can help control the cancer safely after those earlier treatments.
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
This study compares two chemotherapy drugs (raltitrexed and 5-fluorouracil) given directly into the liver's main artery to treat liver cancer. It aims to see which drug works better and is safer for people with hepatocellular carcinoma.
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.